Evidence map›Paper›PMID 25709097›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.

Jose Cortes-Briones, Patrick D Skosnik, Daniel Mathalon, John Cahill, Brian Pittman, Ashley Williams, R Andrew Sewell, Mohini Ranganathan, Brian Roach, Judith Ford and 1 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07681869 (A Randomized Controlled Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07681869 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized Controlled Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers

TypeinterventionalSponsorYale UniversityRan2026 to 2032Enrolled40ConditionsAlcohol Use DisorderArmsNimodipine, Placebo
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  8. Review
  9. Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Effects of Cannabis Consumption on Sleep.Advances in experimental medicine and biology · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jose Cortes-Briones1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Patrick D Skosnik1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [3] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
Daniel Mathalon1] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [2] Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA [3] Mental Health Service Line, San Francisco VA Medical Center, San Francisco, CA, USA.
John Cahill1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [3] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
Brian Pittman1] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [2] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
Ashley Williams1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
R Andrew Sewell1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [3] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
Mohini Ranganathan1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [3] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
Brian Roach1] Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA [2] Mental Health Service Line, San Francisco VA Medical Center, San Francisco, CA, USA.
Judith Ford1] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [2] Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA [3] Mental Health Service Line, San Francisco VA Medical Center, San Francisco, CA, USA.
Deepak Cyril D'Souza1] Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA [3] Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
VA Connecticut Healthcare System · USSan Francisco VA Medical Center · USConnecticut Mental Health Center · US

Funding

Cannabinoids, Neural Synchrony and Information ProcessingR21DA020750 · NIDA · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2007 to 2008
$354k
Intramural VA VA999999NIDA NIH HHS R21 DA020750
6 · The paper itself

Abstract

Gamma (γ)-band oscillations play a key role in perception, associative learning, and conscious awareness and have been shown to be disrupted by cannabinoids in animal studies. The goal of this study was to determine whether cannabinoids disrupt γ-oscillations in humans and whether these effects relate to their psychosis-relevant behavioral effects. The acute, dose-related effects of Δ-9-tetrahydrocannabinol (Δ(9)-THC) on the auditory steady-state response (ASSR) were studied in humans (n=20) who completed 3 test days during which they received intravenous Δ(9)-THC (placebo, 0.015, and 0.03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design. Electroencephalography (EEG) was recorded while subjects listened to auditory click trains presented at 20, 30, and 40 Hz. Psychosis-relevant effects were measured with the Positive and Negative Syndrome scale (PANSS). Δ(9)-THC (0.03 mg/kg) reduced intertrial coherence (ITC) in the 40 Hz condition compared with 0.015 mg/kg and placebo. No significant effects were detected for 30 and 20 Hz stimulation. Furthermore, there was a negative correlation between 40 Hz ITC and PANSS subscales and total scores under the influence of Δ(9)-THC. Δ(9)-THC (0.03 mg/kg) reduced evoked power during 40 Hz stimulation at a trend level. Recent users of cannabis showed blunted Δ(9)-THC effects on ITC and evoked power. We show for the first time in humans that cannabinoids disrupt γ-band neural oscillations. Furthermore, there is a relationship between disruption of γ-band neural oscillations and psychosis-relevant phenomena induced by cannabinoids. These findings add to a growing literature suggesting some overlap between the acute effects of cannabinoids and the behavioral and psychophysiological alterations observed in psychotic disorders.

Indexed as

Acoustic StimulationAdolescentAdultCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodDronabinolElectroencephalographyFemaleFourier AnalysisGamma RhythmHumansMalePsychiatric Status Rating ScalesPsychoacousticsPsychotropic Drugsdelta(9)-tetrahydrocannabinolic acidDronabinolPsychotropic Drugs

Identifiers

PMID25709097
PMCPMC4613601
OpenAlexW2011177087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.